tryptamines

Summary

Summary: Decarboxylated monoamine derivatives of TRYPTOPHAN.

Top Publications

  1. Shiu S, Pang B, Tam C, Yao K. Signal transduction of receptor-mediated antiproliferative action of melatonin on human prostate epithelial cells involves dual activation of G?(s) and G?(q) proteins. J Pineal Res. 2010;49:301-11 pubmed publisher
    ..Our results also showed that dual activation of G?(s) and G?(q) proteins is involved in the signal transduction of MTNR1A receptor-mediated antiproliferative action of melatonin on human prostate epithelial cells...
  2. Loder E. Triptan therapy in migraine. N Engl J Med. 2010;363:63-70 pubmed publisher
  3. Bussone G, Allais G, Castagnoli Gabellari I, Benedetto C. Almotriptan for menstrually related migraine. Expert Opin Pharmacother. 2011;12:1933-43 pubmed publisher
    ..Since MRM may be difficult to treat, it is important to find an appropriate treatment option for women suffering from this condition...
  4. Allais G, Bussone G, D Andrea G, Moschiano F, D Onofrio F, Valguarnera F, et al. Almotriptan 12.5 mg in menstrually related migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2011;31:144-51 pubmed publisher
    ..Because such migraines are often predictable, they provide a suitable target for treatment in the mild pain phase. The present study was designed to provide prospective data on the efficacy of almotriptan for treatment of MRM...
  5. Holloway C, Muratore M, Storer R, Dixon D. Direct enantioselective Brønsted acid catalyzed N-acyliminium cyclization cascades of tryptamines and ketoacids. Org Lett. 2010;12:4720-3 pubmed publisher
    ..diastereoselective N-acyliminium cyclization cascade through chiral phosphoric acid catalyzed condensation of tryptamines with ?- and ?-ketoacid derivatives to provide architecturally complex heterocycles has been developed...
  6. Casolla B, Lionetto L, Candela S, D Alonzo L, Negro A, Simmaco M, et al. Treatment of perimenstrual migraine with triptans: an update. Curr Pain Headache Rep. 2012;16:445-51 pubmed publisher
    ..This review is also intended to offer an updated reasonable guide to physicians treating perimenstrual migraine in daily practice...
  7. Allais G, Tullo V, Omboni S, Benedetto C, Sances G, Zava D, et al. Efficacy of frovatriptan versus other triptans in the acute treatment of menstrual migraine: pooled analysis of three double-blind, randomized, crossover, multicenter studies. Neurol Sci. 2012;33 Suppl 1:S65-9 pubmed publisher
    ..24 % comparators) or at 48 h (15 vs. 26 % comparators). Number of menstrual migraine attacks associated with drug-related adverse events was equally low (P = NS) between F (5 %) and comparators (4 %)...
  8. Chargari C, Leteur C, Angevin E, Bashir T, Schoentjes B, Arts J, et al. Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts. Cancer Lett. 2011;312:209-18 pubmed publisher
    ..Further investigations are warranted with regard to the molecular mechanisms underlying its actions and its dependency regarding p53 status...
  9. Kelman L, Harper S, Hu X, Campbell J. Treatment response and tolerability of frovatriptan in patients reporting short- or long-duration migraines at baseline. Curr Med Res Opin. 2010;26:2097-104 pubmed publisher
    ..Compare migraine duration with frovatriptan (versus baseline) in migraineurs reporting long- (24-72 h) or short-duration (<24 h) migraines at baseline...

More Information

Publications62

  1. Tfelt Hansen P. Published and not fully published double-blind, randomised, controlled trials with oral naratriptan in the treatment of migraine: a review based on the GSK Trial Register. J Headache Pain. 2011;12:399-403 pubmed publisher
    ..The efficacy of naratriptan 2.5 mg versus NSAIDs is not sufficiently investigated. Naratriptan, when available OTC is a reasonable second or third choice on the step care ladder in the acute treatment of migraine. ..
  2. Tfelt Hansen P. Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine. Headache. 2011;51:118-23 pubmed publisher
    ..The introduction of calcitonin gene-related peptide receptor antagonism in the acute treatment of migraine is a major step forward but so far mostly because of its specific mode of action and excellent tolerability...
  3. De Felice M, Ossipov M, Porreca F. Update on medication-overuse headache. Curr Pain Headache Rep. 2011;15:79-83 pubmed publisher
    ..Persistent, pronociceptive adaptations in nociceptors as well as within descending modulatory pathways thus may jointly contribute to the development of MOH...
  4. Rodgers A, Hustad C, Cady R, Martin V, Winner P, Ramsey K, et al. Total migraine freedom, a potential primary endpoint to assess acute treatment in migraine: comparison to the current FDA requirement using the complete rizatriptan study database. Headache. 2011;51:356-368 pubmed publisher
    ..To examine total migraine freedom (TMF), defined as pain freedom and absence of associated symptoms, using rizatriptan clinical trial data and to explore advantages of TMF as a single primary composite efficacy endpoint...
  5. Sheftell F, Almas M, Weeks R, Mathew N, Pitman V, Lipton R. Quantifying the return of headache in triptan-treated migraineurs: an observational study. Cephalalgia. 2010;30:838-46 pubmed publisher
    ..Treatment satisfaction declined with increasing severity of headache return, demonstrating the value of assessing headache return by severity to fully evaluate its impact...
  6. Ferrari A, Spaccapelo L, Sternieri E. Pharmacoepidemiology of triptans in a headache centre. Cephalalgia. 2010;30:847-54 pubmed publisher
    ..The aims of this survey were: (i) to examine the pharmacoepidemiology of triptans in a headache centre; (ii) to compare the characteristics of patients who continued to take triptans with those of patients who had discontinued them...
  7. Terrazzino S, Viana M, Floriddia E, Monaco F, Mittino D, Sances G, et al. The serotonin transporter gene polymorphism STin2 VNTR confers an increased risk of inconsistent response to triptans in migraine patients. Eur J Pharmacol. 2010;641:82-7 pubmed publisher
    ..77). These results support the role of STin2 VNTR polymorphism of serotonin transporter gene as a relevant genetic factor conferring a higher risk of inconsistent response to triptans in migraine patients...
  8. Cai Q, Liu C, Liang X, You S. Enantioselective construction of pyrroloindolines via chiral phosphoric acid catalyzed cascade Michael addition-cyclization of tryptamines. Org Lett. 2012;14:4588-90 pubmed publisher
    ..construction of pyrroloindolines via chiral phosphoric acid catalyzed cascade Michael addition-cyclization of tryptamines has been realized...
  9. Savi L, Omboni S, Lisotto C, Zanchin G, Ferrari M, Zava D, et al. A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine. J Headache Pain. 2011;12:219-26 pubmed publisher
    ..The results suggest that frovatriptan has a similar efficacy to rizatriptan, but a more prolonged duration of action...
  10. Scott F, Belle M, Delagrange P, Piggins H. Electrophysiological effects of melatonin on mouse Per1 and non-Per1 suprachiasmatic nuclei neurones in vitro. J Neuroendocrinol. 2010;22:1148-56 pubmed publisher
    ..The results also suggest that melatonin acts mainly by modulating inhibitory GABAergic transmission within the SCN. This may explain why exogenous application of melatonin has heterogenous effects on individual SCN neurones...
  11. Cortelli P, Allais G, Tullo V, Benedetto C, Zava D, Omboni S, et al. Frovatriptan versus other triptans in the acute treatment of migraine: pooled analysis of three double-blind, randomized, cross-over, multicenter, Italian studies. Neurol Sci. 2011;32 Suppl 1:S95-8 pubmed publisher
    ..05) less under F, particularly cardiovascular symptoms. Our systematic analysis of individual studies suggests that F has a similar immediate efficacy, but a more sustained effect and a better tolerability than R, Z and A...
  12. Allais G, Tullo V, Benedetto C, Zava D, Omboni S, Bussone G. Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, multicenter, Italian, comparative study versus zolmitriptan. Neurol Sci. 2011;32 Suppl 1:S99-104 pubmed publisher
    ..05) lower with frovatriptan (15 vs. 22% zolmitriptan). Frovatriptan proved to be effective in the immediate treatment of MRM attacks, similarly to zolmitriptan, but showed lower recurrence rates, and thus a better sustained relief...
  13. Savi L, Omboni S, Lisotto C, Zanchin G, Ferrari M, Zava D, et al. Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study versus rizatriptan. J Headache Pain. 2011;12:609-15 pubmed publisher
    ..These results need to be confirmed by randomized, double-blind, prospective, large clinical trials...
  14. Bartolini M, Giamberardino M, Lisotto C, Martelletti P, Moscato D, Panascia B, et al. Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study. J Headache Pain. 2012;13:401-6 pubmed publisher
    ..05). Frovatriptan was as effective as almotriptan in the immediate treatment of menstrually related migraine attacks. However, it showed a more favorable sustained effect, as shown by a lower rate of migraine recurrence...
  15. Rizzoli P. Acute and preventive treatment of migraine. Continuum (Minneap Minn). 2012;18:764-82 pubmed publisher
    ..This article focuses on acute and preventive treatment of migraine, including the mechanisms of action, dosing and side effects of medications, and strategies for the most effective care...
  16. Gentile G, Missori S, Borro M, Sebastianelli A, Simmaco M, Martelletti P. Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine. J Headache Pain. 2010;11:151-6 pubmed publisher
    ..Such genomic analysis is part of an integrated platform able to evaluate different levels of metabolic pathways of drugs in CM and their influence in the chronicization process. ..
  17. Antonaci F, De Cillis I, Cuzzoni M, Allena M. Almotriptan for the treatment of acute migraine: a review of early intervention trials. Expert Rev Neurother. 2010;10:351-64 pubmed publisher
    ..Thus, the excellent efficacy and tolerability profile of almotriptan administered early in a migraine attack indicate that it may be a first-line treatment option in this common, underdiagnosed and undertreated disorder...
  18. Tullo V, Allais G, Ferrari M, Curone M, Mea E, Omboni S, et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double-blind, randomized, multicenter, Italian study. Neurol Sci. 2010;31 Suppl 1:S51-4 pubmed publisher
    ..Drug-related adverse events were significantly (p < 0.05) less under F (3 vs. 10). In conclusion, our study suggests that F has a similar efficacy of Z, with some advantage as regards tolerability and recurrence...
  19. MacGregor E, Pawsey S, Campbell J, Hu X. Safety and tolerability of frovatriptan in the acute treatment of migraine and prevention of menstrual migraine: Results of a new analysis of data from five previously published studies. Gend Med. 2010;7:88-108 pubmed publisher
    ..Triptans are a recommended first-line treatment for moderate to severe migraine...
  20. Tabernero J, Dirix L, Schoffski P, Cervantes A, Lopez Martin J, Capdevila J, et al. A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors. Clin Cancer Res. 2011;17:6313-21 pubmed publisher
    ..This study evaluated the safety and tolerability of serdemetan, determined the pharmacokinetic and pharmacodynamic profiles, and identified a recommended phase II dose...
  21. Anwar M, Ford W, Broadley K, Herbert A. Vasoconstrictor and vasodilator responses to tryptamine of rat-isolated perfused mesentery: comparison with tyramine and ?-phenylethylamine. Br J Pharmacol. 2012;165:2191-202 pubmed publisher
    ..Our hypothesis is therefore that the rat mesenteric arterial bed will exhibit vasopressor and vasodepressor responses to tryptamine via both 5-HT and TAARs...
  22. Bartolini M, Giamberardino M, Lisotto C, Martelletti P, Moscato D, Panascia B, et al. A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. J Headache Pain. 2011;12:361-8 pubmed publisher
    ..18%). The tolerability profile was similar between the two drugs. In conclusion, our study suggests that frovatriptan has a similar efficacy of almotriptan in the short-term, while some advantages are observed during long-term treatment...
  23. Silberstein S, Holland S, Freitag F, Dodick D, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337-45 pubmed publisher
    ..To provide updated evidence-based recommendations for the preventive treatment of migraine headache. The clinical question addressed was: What pharmacologic therapies are proven effective for migraine prevention?..
  24. Johnston M, Rapoport A. Triptans for the management of migraine. Drugs. 2010;70:1505-18 pubmed publisher
    ..This paper critically reviews efficacy, safety and tolerability for the different formulations of sumatriptan, zolmitriptan, rizatriptan, naratriptan, almotriptan, eletriptan and frovatriptan...
  25. Romero A, Egea J, Garcia A, Lopez M. Synergistic neuroprotective effect of combined low concentrations of galantamine and melatonin against oxidative stress in SH-SY5Y neuroblastoma cells. J Pineal Res. 2010;49:141-8 pubmed publisher
    ..The synthesis of novel multitarget compounds having in a single molecule the combined neuroprotective properties of galantamine and melatonin could be a new strategy for potential therapeutic agents in neurodegenerative diseases...
  26. Lionetto L, Casolla B, Mastropietri F, D Alonzo L, Negro A, Simmaco M, et al. Pharmacokinetic evaluation of zolmitriptan for the treatment of migraines. Expert Opin Drug Metab Toxicol. 2012;8:1043-50 pubmed publisher
    ..The pharmacologic treatment of migraine is classically divided in the management of the acute attack and preventive strategies. Acute treatments consist of triptan, ergot, opioid, antiemetic and NSAIDs...
  27. Sanford M. Frovatriptan: a review of its use in the acute treatment of migraine. CNS Drugs. 2012;26:791-811 pubmed publisher
  28. Sotthibundhu A, Phansuwan Pujito P, Govitrapong P. Melatonin increases proliferation of cultured neural stem cells obtained from adult mouse subventricular zone. J Pineal Res. 2010;49:291-300 pubmed publisher
    ..Because stem cell replacement is thought to play an important therapeutic role in neurodegenerative diseases, melatonin might be beneficial for stimulating endogenous neural stem cells...
  29. Kojima K, Burks J, Arts J, Andreeff M. The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias. Mol Cancer Ther. 2010;9:2545-57 pubmed publisher
    ..The presence of p53-independent apoptotic activity in addition to p53-mediated apoptosis induction, if operational in vivo, may prevent the selection of p53 mutant subclones during therapy...
  30. Negro A, Lionetto L, Casolla B, Lala N, Simmaco M, Martelletti P. Pharmacokinetic evaluation of frovatriptan. Expert Opin Drug Metab Toxicol. 2011;7:1449-58 pubmed publisher
    ..Today, a total of seven triptan molecules are available, representing a commonly prescribed migraine treatment. Although there is a need of extensive use of triptans, only 25% of migraine patients are using triptans...
  31. MacGregor E. Prevention and treatment of menstrual migraine. Drugs. 2010;70:1799-818 pubmed publisher
    ..5?mg, frovatriptan 2.5?mg twice daily and naratriptan 1?mg twice daily. Contraceptive strategies offer the opportunity for treating menstrual migraine in women who also require effective contraception...
  32. Meng I, Dodick D, Ossipov M, Porreca F. Pathophysiology of medication overuse headache: insights and hypotheses from preclinical studies. Cephalalgia. 2011;31:851-60 pubmed publisher
    ..Medications that can cause MOH include opioid analgesics as well as formulations designed for the treatment of migraine, such as triptans, ergot alkaloids, or drug combinations that include caffeine and barbiturates...
  33. Pavone E, Banfi R, Vaiani M, Panconesi A. Patterns of triptans use: a study based on the records of a community pharmaceutical department. Cephalalgia. 2007;27:1000-4 pubmed
    ..Our data indicate suboptimal treatment of migraine patients and also incorrect treatment of some patients (potential triptans abusers, the elderly)...
  34. Rapoport A. Acute treatment of headache. J Headache Pain. 2006;7:355-9 pubmed
    ..The effectiveness of the 7 available triptans in early, double-blind, controlled trials is more similar than different. How and when to give them will be discussed. Treatment of cluster headache will be presented briefly...
  35. Seayad J, Seayad A, List B. Catalytic asymmetric Pictet-Spengler reaction. J Am Chem Soc. 2006;128:1086-7 pubmed
    A catalytic asymmetric Pictet-Spengler reaction has been developed, wherein treating substituted tryptamines with an aldehyde in the presence of a catalytic amount of a chiral phosphoric acid provides the corresponding tetrahydro-beta-..
  36. Radogna F, Paternoster L, Albertini M, Cerella C, Accorsi A, Bucchini A, et al. Melatonin antagonizes apoptosis via receptor interaction in U937 monocytic cells. J Pineal Res. 2007;43:154-62 pubmed
    ..Secondly, melatonin's antiapoptotic effect required key signal transduction events including G protein, phospholipase C and Ca(2+) influx and, more important, it is sensitive to the specific melatonin receptor antagonist luzindole...
  37. Allais G, Acuto G, Cabarrocas X, Esbri R, Benedetto C, Bussone G. Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurol Sci. 2006;27 Suppl 2:S193-7 pubmed
    ..7% for zolmitriptan. Adverse events in the 24 h after dosing were reported by 19.8% of those taking almotriptan and 23.1% of those taking zolmitriptan. In conclusion, almotriptan is effective and safe in the treatment of MM attacks...
  38. Winter J. Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines. Psychopharmacology (Berl). 2009;203:251-63 pubmed publisher
    ..Stimulus control by hallucinogens has provided an intuitively attractive approach to the study of these agents in nonverbal species...
  39. McCormack P, Keating G. Eletriptan: a review of its use in the acute treatment of migraine. Drugs. 2006;66:1129-49 pubmed
    ..Eletriptan is therefore a useful addition to the triptan family and a first-line treatment option in the acute management of migraine attacks...
  40. Linde M, Mellberg A, Dahlof C. The natural course of migraine attacks. A prospective analysis of untreated attacks compared with attacks treated with a triptan. Cephalalgia. 2006;26:712-21 pubmed
    ..Hyperexcitability can respond before pain to treatment. These genuine findings of the classic symptoms of migraine attacks support the notion of a mutual underlying pathophysiological mechanism...
  41. Lambert G. Preclinical neuropharmacology of naratriptan. CNS Drug Rev. 2005;11:289-316 pubmed
    ..The mechanism of action involved in the production of behavioral and other CNS side effects of naratriptan is unknown...
  42. Humphrey P. The discovery of a new drug class for the acute treatment of migraine. Headache. 2007;47 Suppl 1:S10-9 pubmed
  43. Mannix L, Savani N, Landy S, Valade D, Shackelford S, Ames M, et al. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies. Headache. 2007;47:1037-49 pubmed
  44. Tuchman M, Hee A, Emeribe U, Silberstein S. Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study. CNS Drugs. 2008;22:877-86 pubmed
    ..To evaluate the efficacy and tolerability of oral zolmitriptan as a short-term preventative therapy for menstrual migraine...
  45. Hargreaves R, Lines C, Rapoport A, Ho T, Sheftell F. Ten years of rizatriptan: from development to clinical science and future directions. Headache. 2009;49 Suppl 1:S3-20 pubmed publisher
  46. Ho T, Fan X, Rodgers A, Lines C, Winner P, Shapiro R. Age effects on placebo response rates in clinical trials of acute agents for migraine: pooled analysis of rizatriptan trials in adults. Cephalalgia. 2009;29:711-8 pubmed publisher
    ..Age appeared to be an important predictor of placebo response rate in rizatriptan trials, with older patients being less likely to respond to placebo and more likely to respond to rizatriptan...
  47. Furman J, Marcus D. A pilot study of rizatriptan and visually-induced motion sickness in migraineurs. Int J Med Sci. 2009;6:212-7 pubmed
    ..The present study was designed to test whether rizatriptan is also effective in protecting against visually-induced motion sickness and to test whether rizatriptan blocks the augmentation of motion sickness by head pain...
  48. Cady R, Banks J, Jones B, Campbell J. Postmarketing migraine survey of frovatriptan: effectiveness and tolerability vs previous triptans, NSAIDs or a combination. Curr Med Res Opin. 2009;25:2711-21 pubmed publisher
    ..5-mg tablets (in 1-3 migraines) in patients with migraine previously using other triptans, analgesics/nonsteroidal anti-inflammatory drugs (NSAIDs), or triptans and NSAIDs (T+NSAIDs)...
  49. Ruddick J, Evans A, Nutt D, Lightman S, Rook G, Lowry C. Tryptophan metabolism in the central nervous system: medical implications. Expert Rev Mol Med. 2006;8:1-27 pubmed
  50. Goldstein J, Tiseo P, Albert K, Li C, Sikes C. Eletriptan in migraine patients reporting unsatisfactory response to rizatriptan. Headache. 2006;46:1142-50 pubmed
  51. Asuni C, Cherchi A, Congiu D, Piccardi M, Del Zompo M, Stochino M. Association study between clinical response to rizatriptan and some candidate genes. J Headache Pain. 2007;8:185-9 pubmed
    ..03) of DRD2/NcoI. The significant association with the DRD2/NcoI polymorphism in responders suggested that the DRD2/NcoI C allele may be considered a susceptibility factor heralding a good response to rizatriptan...
  52. Dodick D, Lipton R, Goadsby P, Tfelt Hansen P, Ferrari M, Diener H, et al. Predictors of migraine headache recurrence: a pooled analysis from the eletriptan database. Headache. 2008;48:184-93 pubmed publisher
  53. Muratore M, Holloway C, Pilling A, Storer R, Trevitt G, Dixon D. Enantioselective Brønsted acid-catalyzed N-acyliminium cyclization cascades. J Am Chem Soc. 2009;131:10796-7 pubmed publisher
    An enantioselective Brønsted acid-catalyzed N-acyliminium cyclization cascade of tryptamines with enol lactones to form architecturally complex heterocycles in high enantiomeric excess has been developed...